Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

FA02.06: VOLUMETRIC LASER ENDOMICROSCOPY GLAND QUANTIFICATION CAN GUIDE EN-BLOC RESECTION IN DYSPLASTIC BARRETT’S ESOPHAGUS
Kamboj, Amrit K. , Sawas, Tarek , Lutzke, Lori S., Kahn, Allon , Wang, Kenneth , Leggett, Cadman L.

Mayo Clinic

Diseases of the Esophagus | September 14, 2018 | Volume: 31 | Issue: Supplement_1 | Pages: 4-5

10.1093/dote/doy089.fa02.06 Get It

Abstract Background Endoscopic mucosal resection (EMR) can be performed en-bloc in Barrett's esophagus (BE) lesions that are ≤2 cm in size. The true size of a BE lesion may be underestimated under white light endoscopy, limiting the rate of en-bloc resection. Volumetric laser endomicroscopy (VLE) provides high-resolution cross-sectional imaging of BE. A greater number of VLE glands are associated with BE dysplasia and may help predict lesion size. The aim of this study was to determine the association between VLE gland count and outcome of resection. Methods EMR specimens from patients with a history of dysplastic BE were imaged with VLE. EMRs performed on BE lesions ≤2cm in size with intent at en-bloc resection were included. Manual quantification of epithelial glands was performed in blinded fashion. Image visualization enhancement software was used to quantify the surface area occupied by epithelial glands on en-face VLE. Histologic en-bloc (R0) and incomplete (R1) resection of the targeted lesion was defined by the absence and presence of dysplasia and/or cancer at the specimen margins respectively. Results The study sample consisted of 37 EMRs from 31 patients. The mean (SD) size of EMRs was 1.04 (0.37) cm. Pathology showed low-grade dysplasia (N = 12), high-grade dysplasia (N = 19), and intramucosal cancer (N = 6). The en-bloc resection rate was 37.8% (R0: N = 14; R1: N = 23). The mean (SD) number of epithelial glands was 13.0 (6.7) and 28.8 (23.9) for R0 and R1 specimens, respectively, with a statistically significant mean difference of 15.8 glands (95% CI: 2–29, P = 0.02) between the two groups. A gland count of 28 or higher per EMR specimen predicted R1 with 100% sensitivity and 39% specificity (ROC: 0.69). The mean (SD) surface area occupied by epithelial glands in R0 and R1 specimens was 0.98 (1.1) mm2 and 2.3 (2.4) mm2, respectively. There was strong correlation between manual gland counts and epithelial gland surface area (R2: 0.81, P < 0.001). Conclusion A higher number of VLE glands in EMR specimens is associated with a lower en-bloc resection rate suggesting that white-light endoscopy underestimates lesion size and that VLE may have a potential role in lesion margin assessment. Disclosure All authors have declared no conflicts of interest.
Macroautophagy Regulates Nuclear NOTCH1 Activity Through Multiple p62 Binding Sites
Guo, Lixia , Yang, Yanan , Yang, Yanan , Yang, Yanan , Zhang, Ting , Wang, Yuanyuan , Yang, Yanan

Mayo Clinic

IUBMB Life | September 12, 2018 | Volume: 70 | Issue: 10 | Pages: 985-994

10.1002/iub.1891 | PMID 30207627 Get It

AbstractNOTCH1 is the prototype of the NOTCH family of single‐pass transmembrane receptors and regulates many basic processes during embryonic development and human pathogenesis. In core to NOTCH1 activation are proteolytic cleavages that release its intracellular domain (NICD1), which in turn translocates to the nucleus to regulate gene transcription. Macroautophagy (hereafter autophagy) has been shown to promote the degradation of NOTCH1, but the underlying mechanisms remain elusive. Here, we show that autophagy promotes the degradation of NOTCH1 by p62‐dependent binding between NICD1 and LC3, a component of the autophagosomes that execute autophagy. Strikingly, deleting any of the structural NICD1 domains fails to block the degradation of NICD1 by autophagy, and p62 binds to almost all these domains independently, indicating that p62 binds to multiple sites on NICD1 to promote its degradation. Intriguingly, inhibition of autophagy induces the accumulation of NICD1 in not only the cytoplasm but also the nucleus and increases the transcriptional activity of NICD1, and such regulation of nuclear NICD1 by autophagy is unique to NICD1 and not observed for all other NICDs (NICD2‐4). Collectively, our results suggest that autophagy tightly controls nuclear NOTCH1 activity through multiple p62 binding sites, and that modulating autophagy activity may be useful for treating NOTCH1 related human diseases. © 2018 IUBMB Life, 70(10):985–994, 2018
Extracting chemical–protein relations using attention-based neural networks
Liu, Sijia , Shen, Feichen , Elayavilli, Ravikumar Komandur, Wang, Yanshan , Chaudhary, Vipin , Komandur Elayavilli, Ravikumar, Rastegar-Mojarad, Majid, Liu, Sijia , Rastegar-Mojarad, Majid , Liu, Hongfang , Wang, Yanshan

Mayo Clinic

Database | September 11, 2018 | Volume: 2018 | Issue: No issue available | Pages: No page available

10.1093/database/bay102 | PMID 30295724 Get It

3D MR Elastography of Hepatocellular Carcinomas as a Potential Biomarker for Predicting Tumor Recurrence
Shan, Qungang , Yang, Hao , Kuang, Sichi , He, Bingjun , Zhang, Yao , Chen, Jingbiao , Zhang, Tianhui , Glaser, Kevin J. , Yin, Meng , Venkatesh, Sudhakar K. , Venkatesh, Sudhakar K , Yin, Meng , Wang, Jin , Liu, Yong , Zhu, Cairong , Chen, Jun , Ehman, Richard L.

Mayo Clinic

Journal of Magnetic Resonance Imaging | September 8, 2018 | Volume: 49 | Issue: 3 | Pages: 719-730

10.1002/jmri.26250 | PMID 30260529 Get It

BackgroundPreoperative prediction of tumor recurrence is important in the management of patients with hepatocellular carcinoma (HCC).PurposeTo investigate whether tumor stiffness derived by magnetic resonance elastography (MRE) could predict early recurrence of HCC after hepatic resection.Study TypeRetrospective.PopulationIn all, 99 patients with pathologically confirmed HCCs after surgical resection.Field Strength/Sequence3.0T; preoperative MRE with 60‐Hz mechanical vibrations using an active acoustic driver.AssessmentRegions of interest (ROIs) were manually drawn in the tumors to measure mean tumor stiffness. Surgical specimens were reviewed for histological grade, capsule, vascular invasion, and surgical margins. The early recurrence of HCC was defined as that occurring within 2 years after resection.Statistical TestsCox proportional hazard models were used to evaluate risk factors associated with the time to early recurrence.ResultsHCCs with recurrence had higher tumor stiffness, higher rate of advanced T stage, vascular invasion, lower rate of capsule formation, larger tumor size, higher aspartate aminotransferase (AST), and hepatitis B virus (HBV)‐DNA level and aspartate aminotransferase / alanine aminotransferase ratio (P = 0.031, 0.007, 0.01, <0.001, 0.015, 0.034, 0.01, and 0.014, respectively) than HCCs without recurrence. Vascular invasion (hazard ratio [HR] = 2.922; 95% confidence interval [CI]: [1.079, 7.914], P = 0.035) and mean tumor stiffness (HR = 1.163; 95% CI: [1.055, 1.282], P = 0.002) were risk factors associated with early recurrence. Each 1‐kPa increase in tumor stiffness was associated with a 16.3% increase in the risk for tumor recurrence.Data ConclusionThe mean stiffness of HCCs may be a useful, noninvasive, quantitative biomarker for the prediction of early HCC recurrence after hepatic resection.Level of Evidence: 4Technical Efficacy: Stage 5J. Magn. Reson. Imaging 2019;49:719–730.
Adiposity Genetic Risk Score Modifies the Association Between Blood Lead Level and Body Mass Index
Wang, Ningjian , Lu, Meng , Chen, Chi , Xia, Fangzhen , Han, Bing , Cheng, Jing , Jensen, Michael D. , Lu, Yingli , Li, Qin , Chen, Yi , Zhu, Chunfang

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | September 7, 2018 | Volume: 103 | Issue: 11 | Pages: 4005-4013

10.1210/jc.2018-00472 | PMID 30202913 Get It

Abstract Context Previous epidemiological studies had inconsistent results regarding the relationship between blood lead level (BLL) and adiposity. Objective We aimed to investigate the associations of BLL with body mass index (BMI) particularly using Mendelian randomization analyses and examine the interaction between obesity-predisposing genes and BLL on the associations. Design and Setting A total of 3922 participants were enrolled from 16 sites in East China in 2014 from the Survey on Prevalence in East China for Metabolic Diseases and Risk Factors (ChiCTR-ECS-14005052, www.chictr.org.cn). We calculated the weighted BMI genetic risk score (GRS) based on 29 variants that were identified and validated in East Asians. BLL was measured by atomic absorption spectrometry. Main Outcome Measure BMI was calculated, and BMI ≥25 kg/m2 was defined as overweight. Results Multivariable logistic regression analysis demonstrated significant associations between BMI with each unit increase in lnBLL (β = 0.24; 95% CI, 0.08 to 0.40; P &lt; 0.001) and each 1-point increase in BMI-GRS (β = 0.08; 95% CI, 0.05 to 0.11; P &lt; 0.001). The causal regression coefficients of genetically determined BMI for lnBLL were −0.003 (95% CI, −0.075 to 0.070), which showed no significance. The GRS modified the association of BLL with BMI and overweight (BMI ≥25 kg/m2; P for interaction = 0.031 and 0.001, respectively). Each unit of lnBLL was associated with 63% higher odds of overweight (OR 1.63; 95% CI, 1.30 to 2.05) in the highest quartile of GRS, but no significant associations were found in the lower three quartiles. Conclusions The associations of BLL with BMI and overweight (BMI ≥25 kg/m2) were significantly modulated by BMI genetic susceptibility.
Developing tools to enhance the use of systematic reviews for clinical care in health systems
Morrow, Allison S. , Whiteside, Stephen P. H. , Sim, Leslie , Brito, Juan P. , Murad, M. Hassan , Whiteside, Stephen P., Murad, M Hassan , Brito, Juan P , Wang, Zhen

Mayo Clinic

BMJ Evidence-Based Medicine | September 7, 2018 | Volume: 23 | Issue: 6 | Pages: 206-209

10.1136/bmjebm-2018-110995 | PMID 30194075 Get It

We aimed to develop tools that can facilitate uptake of evidence summarised in systematic reviews by clinical decision makers in health systems. After conducting a systematic review on the management of anxiety in children, we interviewed health system representatives, clinicians and patients to ask about additional information needed for decision-making. Using stakeholders’ feedback and literature searches for contextual and implementation information, we developed two tools (decision aids (DAs)), one for the health system and the second for the clinical encounter. This information mapped to factors of the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) Evidence to Decision Framework. The health system DAs provided information on which patients are candidate for treatment, values and preferences, costs and resources, acceptability, impact on health equity, feasibility, drug dosing, alternative therapies, remission rates and prognosis. Health system stakeholders found the DA useful for clinical decision-making and generalisable to other conditions. The encounter DA was produced as cards containing information on issues that drive treatment decisions (effect on symptoms, effect on function, treatment burden, side effects and cost). Patients and parents prioritised the cards and chose the order in which these issues were discussed with clinician. The encounter DA was found to be helpful by patients, parents and clinicians. We conclude that the uptake of evidence summaries by health systems can be enhanced by developing tools that provide contextual and implementation information about clinical care. A dual approach addressing health system stakeholders as well as clinicians and patients is likely feasible and helpful.
Author response: tp53 deficiency causes a wide tumor spectrum and increases embryonal rhabdomyosarcoma metastasis in zebrafish
Hayes, Madeline N. , Moore, Finola E., Tang, Qin , Blackburn, Patrick R. , Ramakrishnan, Ashwin , Reeder, Sophia M. , Nielsen, G. Petur , Hasserjian, Robert P. , Langenau, David M. , Ignatius, Myron S. , Garcia, Sara P. , Baxi, Kunal , Wang, Long, Jin, Alexander , Chen, Yidong , Chen, Eleanor Y. , Tirode, Franck , Ekker, Stephen C.

Mayo Clinic

No container title available | September 7, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.37202.032 Get It

tp53 deficiency causes a wide tumor spectrum and increases embryonal rhabdomyosarcoma metastasis in zebrafish
Hayes, Madeline N. , Moore, Finola E., Tang, Qin , Blackburn, Patrick R. , Baxi, Kunal , Wang, Long , Jin, Alexander , Ramakrishnan, Ashwin , Reeder, Sophia M. , Nielsen, G. Petur , Hasserjian, Robert P. , Tirode, Franck , Ekker, Stephen C. , Langenau, David M. , Tang, Qin , Blackburn, Patrick , Tirode, Franck , Ekker, Stephen C , Langenau, David M , Ignatius, Myron S. , Garcia, Sara P. , Chen, Yidong , Chen, Eleanor Y.

Mayo Clinic

eLife | September 7, 2018 | Volume: 7 | Issue: No issue available | Pages: No page available

10.7554/elife.37202 | PMID 30192230 Get It

The TP53 tumor-suppressor gene is mutated in >50% of human tumors and Li-Fraumeni patients with germ line inactivation are predisposed to developing cancer. Here, we generated tp53 deleted zebrafish that spontaneously develop malignant peripheral nerve-sheath tumors, angiosarcomas, germ cell tumors, and an aggressive Natural Killer cell-like leukemia for which no animal model has been developed. Because the tp53 deletion was generated in syngeneic zebrafish, engraftment of fluorescent-labeled tumors could be dynamically visualized over time. Importantly, engrafted tumors shared gene expression signatures with predicted cells of origin in human tissue. Finally, we showed that tp53del/del enhanced invasion and metastasis in kRASG12D-induced embryonal rhabdomyosarcoma (ERMS), but did not alter the overall frequency of cancer stem cells, suggesting novel pro-metastatic roles for TP53 loss-of-function in human muscle tumors. In summary, we have developed a Li-Fraumeni zebrafish model that is amenable to large-scale transplantation and direct visualization of tumor growth in live animals.
Two phase 3 studies of the oral proteasome inhibitor (PI) ixazomib for multiple myeloma (MM) in the maintenance setting: TOURMALINE-MM3, and -MM4.
Palumbo, Antonio , Iida, Shinsuke , Mateos, María‐Victoria , Goldschmidt, Hartmut , Labotka, Richard, Suryanarayan, Kaveri , Bacco, Alessandra Di , Liao, Eileen , Wang, Bingxia , Morgan, Gareth J. , Rajkumar, S. Vincent , Lonial, Sagar , Chng, Wee Joo , Beksaç, Meral , Dimopoulos, Meletios Α.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: TPS8068-TPS8068

10.1200/jco.2016.34.15_suppl.tps8068 Get It

A pooled analysis of concurrent chemoradiotherapy (CCRT) for patients with stage III non-small cell lung cancer (NSCLC) who participated in U.S. cooperative group trials: Comparing the outcomes of elderly to younger patients (pts).
Stinchcombe, Tom, Zhang, Ying J., Schiller, Joan H. , Curran, Walter J. , Movsas, Benjamin , Clamon, Gerald H., Blumenschein, George R. , Ready, Neal , Akerley, Wallace , Cohen, Harvey Jay, Wang, Xiaofei F., Stinchcombe, Thomas E. , Vokes, Everett E. , Bradley, Jeffrey D. , Schild, Steven E. , Govindan, Ramaswamy , Socinski, Mark A. , Pang, Herbert

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 8508-8508

10.1200/jco.2016.34.15_suppl.8508 Get It